iCAD Launches ProFound Insights, ProFound Impact Webinar Series on April 27
First event to feature Kettering
Health, a leading enterprise breast care provider with 14 breast centers across
southwest Ohio
NASHUA, N.H. – April 19, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced that it will
launch a new webinar series, ProFound Insights, ProFound Impact, which will highlight
customer success stories throughout the year. The first event, “Why
Kettering Health Traded out Previous AI Software for ProFound AI®
Enterprise-Wide” will take place on Wednesday, April 27 from 1-2 pm EDT,
featuring distinguished
clinical and administrative experts from Kettering Health, a leading enterprise breast
care provider with 14 breast centers across southwest Ohio. The event will be moderated by iCAD’s
President and CEO, Stacey Stevens. Visit this
link to register.
Featured panelists include:
- Sally Grady, Director of Kettering Health Breast
Centers - Meghan Musser, DO, Medical Director for Breast Imaging,
Kettering Health
“ProFound AI is a game changer.
Other AI technologies for DBT seem like smoke and mirrors when compared with
ProFound AI. It is clearly the most advanced technology of its kind on the
market, and we found it was going to fit well within the other components we
offer in our screening program.”– Sally Grady, Director of Kettering Health
Breast Centers
“ProFound AI has been something
that we as radiologists have started to depend on and really want. Now that we
have it available for all our patients coming in, it makes a big difference in
our reading efficiency and in the care that we offer. Even the most skeptical
of our breast radiologists are now on board with ProFound AI.” — Meghan
Musser, DO, Medical Director for Breast Imaging, Kettering Health
About iCAD, Inc.
Headquartered in
Nashua, NH, iCAD® is a global medical technology leader providing innovative
cancer detection and therapy solutions. For more information, visit www.icadmed.com.
Forward-Looking Statements
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995, including statements about the expected benefits
of ProFound AI®, the benefits of the Company’s products, and future prospects
for the Company’s technology platforms and products. Such forward-looking
statements involve a number of known and unknown risks, uncertainties and other
factors which may cause the actual results, performance, or achievements of the
Company to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited, to the Company’s ability to achieve
business and strategic objectives, the willingness of patients to undergo
mammography screening in light of risks of potential exposure to Covid-19,
whether mammography screening will be treated as an essential procedure,
whether ProFound AI will improve reading efficiency, improve specificity and
sensitivity, reduce false positives and otherwise prove to be more beneficial
for patients and clinicians, the impact of supply and manufacturing constraints
or difficulties on our ability to fulfill our orders, uncertainty of future
sales levels, to defend itself in litigation matters, protection of patents and
other proprietary rights, product market acceptance, possible technological
obsolescence of products, increased competition, government regulation, changes
in Medicare or other reimbursement policies, risks relating to our existing and
future debt obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed in the
Company’s filings with the Securities and Exchange Commission. The words
“believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue reliance on
those forward-looking statements, which speak only as of the date the statement
was made. The Company is under no obligation to provide any updates to any
information contained in this release. For additional disclosure regarding
these and other risks faced by iCAD, please see the disclosure contained in our
public filings with the Securities and Exchange Commission, available on the
Investors section of our website at http://www.icadmed.com and on the SEC’s
website at http://www.sec.gov.
Contact:
Media
Inquiries:
Jessica
Burns, iCAD
+1-201-423-4492
Investor
Inquiries:
iCAD
Investor Relations